



Product Specification Sheet

EpiSep Anti-Urothelial (LBS8)[®] Magnetic Particles

FOR RESEARCH USE ONLY: This product is not for diagnostic or therapeutic use.

Doc.# ML081003-11

CATALOG #: R2126-1

DESCRIPTION: EpiSep Anti-Urothelial (LBS8)[®] Magnetic Particles are submicron uniform diameter, paramagnetic beads coated with mouse monoclonal LBS8 antibody. The LBS8 antibody recognizes only human urothelium. Urothelium consist of about 3-5 cell layers with a thick layer of protective glycoprotein plaques at its luminal surface.

FOR RESEARCH USE ONLY: This product is not for diagnostic or therapeutic use.

SUPPLIED AS: 1.0 mL of suspended magnetic particles in 0.020M Phosphate Buffer pH 7.4, 0.150M NaCl, 1.0% BSA, 0.1% Sodium Azide. Approximately 1mg/mL.

STABILITY: Recommended storage upon receipt is 4-8°C. **DO NOT FREEZE.** Stable when stored at 4-8°C. Can be stored for up to 12 months at 4-8°C. **DO NOT STORE AT ROOM TEMP.**

APPLICATIONS AND SUGGESTED USE:

Enrichment of urothelial cells for use with FISH, Immunocytochemistry, Flow Cytometry and PCR.

Re-suspend particles prior to each use by inversion several times. Generally, 25 μ L to 100 μ L of particles will be sufficient to capture cells in most specimens.

RELATED PRODUCTS:

EpiSep Alcohol Fixative[™] (Cat#R2114-1)
EpiSep Hybridization Slide[™] (Cat#A3104-10)
NeoMag Slide Dock for Hybridization Slide[™] (Cat#A1103-1)
Magnetic Tube Dock, 50mL[™] (Cat#A4101-1)

APPLICATION

SHEETS: EpiSep Preparation and Isolation of Urothelial Cells from Preserved Urine for use with FISH. (Ref. Doc#ML080612-1)

MATERIAL

SAFETY DATA: When handling this material Standard Laboratory Practices should be followed. This material's chemical, physical and toxicological properties have not been thoroughly investigated. Contains Sodium Azide as a preservative. Although, the quantity of sodium azide (0.1%) is very small, measures should be taken to avoid skin and eye contact, inhalation and ingestion. Sodium Azide (NaN₃) may react with lead and copper plumbing to form potentially explosive metal oxides. Upon disposal, flush with a large volume of water to prevent Azide build-up.

REFERENCES:

1. Trejdosiewicz, L.K. 1985. Monoclonal antibodies to human urothelial cell lines and hybrids: production and characterization. *J Urol.* 133: 533-538.
2. Lorusso, V., Crucitta, E., Silvestris, N., Rosati, G., Manzione, L., De Lena, M., Palmeri, S., Gebbia, V., Mancarella, S., Sobrero, A., Pezzella, G., Comella, P., Mangiameli, A. and Muci, D. 2005. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the Urothelium. *Oncol. Rep.* 13: 283-287.
3. von der Maase, H. 2005. Pemetrexed in transitional cell carcinoma of the Urothelium. *Oncology* 18: 48-50.
4. Wein, A.J. 2005. Role of the Urothelium in bladder function. *J. Urol.* 173: 2199-2200.
5. Woodroffe, P.J., King, J.R., Varley, C.L. and Southgate, J. 2005. Modelling cell signalling and differentiation in the Urothelium. *Bull. Math Biol.* 67: 369-389.
6. Bellmunt, J., Albiol, S., de Olano, A.R., Pujadas, J. and Maroto, P. 2006. Gemcitabine in the treatment of advanced transitional cell carcinoma of the Urothelium. *Ann. Oncol.* 17 Suppl 5: v113-v117.
7. Khattab, M.M. and Al-Hrasen, M.N. 2006. Contractile activity of ATP and diadenosine tetraphosphate on urinary bladder in the rats: role of superoxide anion and Urothelium. *Auton. Autacoid Pharmacol.* 26: 149-156.
8. Lazzeri, M. 2006. The physiological function of the Urothelium—more than a simple barrier. *Urol. Int.* 76: 289-295.
9. Yoshida, M., Inadome, A., Maeda, Y., Satoji, Y., Masunaga, K., Sugiyama, Y. and Murakami, S. 2006. Non-neuronal cholinergic system in human bladder Urothelium. *Urology* 67: 425-430.